Top Suppliers:I want be here




95635-56-6

95635-56-6 structure
95635-56-6 structure
  • Name: Ranolazine dihydrochloride
  • Chemical Name: Ranolazine dihydrochloride
  • CAS Number: 95635-56-6
  • Molecular Formula: C24H35Cl2N3O4
  • Molecular Weight: 500.458
  • Catalog: Biochemical Inhibitor Transmembrane Transporters Calcium Channel Inhibitor
  • Create Date: 2018-02-16 08:00:00
  • Modify Date: 2024-01-02 13:33:20
  • Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value:Target: sodium-dependent calcium channelRanolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.

Name Ranolazine dihydrochloride
Synonyms Ranolazine dihydrochloride
RANOLAZINE HCL
MFCD03788770
RANOLAZINE DI HCL
Ranolazine (dihydrochloride)
N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazinyl}acetamide dihydrochloride
Ranolazine DiHCI
Ranolazine and salt
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, hydrochloride (1:2)
Ranolazine Dihydrocloride
Ranolazine 2HCl
N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide dihydrochloride
Ranolazine dihydroch
Description Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value:Target: sodium-dependent calcium channelRanolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.
Related Catalog
References

[1]. Hawwa N, Menon V. Ranolazine: Clinical Applications and Therapeutic Basis. Am J Cardiovasc Drugs. 2013 Jan 19.

[2]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73.

[3]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.

[4]. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008 Mar;153(6):1128-32. Epub 2007 Dec 10.

[5]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

Boiling Point 624.1ºC at 760 mmHg
Melting Point 222-229.5ºC(lit.)
Molecular Formula C24H35Cl2N3O4
Molecular Weight 500.458
Exact Mass 499.200470
PSA 74.27000
LogP 3.86080
Appearance solid | off-white
Storage condition Desiccate at RT
Water Solubility H2O: 10 mg/mL, soluble
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases S22-S24/25
RIDADR NONH for all modes of transport
WGK Germany 3
HS Code 2942000000
HS Code 2942000000